NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
ProQR Therapeutics N.v. PRQR
11 fiscal years on record · EUR · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
EUR 15.9M
Revenue, FY2025 · full 11-year series below
Revenue €M
Net income €M
FY2025 · Revenue 15.9 · Net income -42.2
10.0M20.0M-25.0M-50.0M
20152018202120242025
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−265 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -273.1% · Net -265.2%
-2000%-4000%
201520202025
ROE
FY2025 · ROE -61.2%
-50%
201520202025
Three returns, three denominators.
Each EUR of equity lost 61 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income €B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA €B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax €B | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ |
| Net income €B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow €B | −0.1 | −0.0 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted € | −0.40 | −0.32 | −0.35 | −0.90 | −0.95 | −0.93 | −1.38 | ◌ | ◌ | ◌ | ◌ |
| Dividend / sh € | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −61.2 | −42.7 | −51.9 | −71.2 | −71.1 | −61.5 | −60.3 | −55.8 | −94.4 | −54.7 | −23.2 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Compare
This company against its peers
ProQR Therapeutics N.v.vsSanofiSame industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsGrifols SASame industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsLakefront Biotherapeutics NVSame industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsEvotec SESame industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsAscendis Pharma A/SSame industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsNanobiotix S.a.Same industry: Pharmaceutical PreparationsProQR Therapeutics N.v.vsInventiva S.a.Same industry: Pharmaceutical Preparations
Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED
Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 12 checks were skipped: EPS is not tagged before 2019.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2015